Navigation Links
Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
Date:11/29/2007

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. dollars) for Galapagos.

The collaboration will combine two key strengths of BioFocus DPI expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called CFTR - cystic fibrosis transmembrane conductance regulator. To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.

Under the terms of the agreement, Galapagos stands to receive up to 1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to 3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.

This drug discovery collaboration is in addition to an ongoing target discovery program established between CFFT and BioFocus DPI in April 2005.

We are excited to take advantage of the innovative drug discovery approach developed by BioFocus DPI and the companys extensive expertise in natural compounds, said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.

The CFFT drug discovery collaboration is a prime example of the kind of innovation we aimed to achieve through our acquisition strategy, said Onno van de Stolpe, CEO of Galapagos. We have seen a growing interest in natural product based drug discovery since acquiring these capabilities last year. By combining this expertise with our know-how in cell-based screening, we are confident that we will contribute to the advancement of CFFTs drug discovery program in novel ways.


'/>"/>

Contact: Lily Mccutchan
lmccutchan@cff.org
301-841-2674
Cystic Fibrosis Foundation
Source:Eurekalert

Related biology news :

1. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
2. Balzan Foundation announces 2007 winners
3. Keck Foundation funds study of biological interactions with nanomaterials
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
6. Simons Foundation awards Emory scientists $3M for autism gene research
7. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
8. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. LaserCard Corporation Announces Expansion of Middle East Project
11. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):
(Date:7/16/2017)... (PRWEB) , ... July 16, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Extreme ... ideal for applications that require CO2 and humidity for optimal cell growth such ...
(Date:7/14/2017)... ... 14, 2017 , ... Sonic Manufacturing Technologies is proud to ... a solar system on its roof top. “We will be independent of the ... Raab stated. The company’s proud history of social responsibility and participation in the ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine Standards ... US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System analyzers. ... D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers five ...
(Date:7/13/2017)... ... July 13, 2017 , ... Thousands of pilots from across the country will ... Championships (Nats). Pilots come to Muncie to compete in various categories of model flying ... that participate in world championships. , RC Pylon (July 14-21): One of the most ...
Breaking Biology Technology: